MedTrace Logo

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2024-12-09

No results posted yet for this study

Summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Conditions

  • Lateral Canthal Lines, LCL
  • Crow's Feet

Interventions

BIOLOGICAL

Vehicle

topical liniment without investigational product

BIOLOGICAL

botulinum toxin, Type A

ET-01 topical liniment

Sponsors & Collaborators

  • Eirion Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2024-02-08
Completion
2024-02-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04985916 on ClinicalTrials.gov